Business Update

Thrombus program moves forward; patent granted for peptide-based contrast agents

Published in Health and Medicine Week, March 13th, 2006

EPIX Pharmaceuticals, Inc., (EPIX), a developer of pharmaceuticals for magnetic resonance imaging, announced that the United States Patent Office has issued U.S. patent no. 6,991,775, a composition-of-matter patent providing coverage for a large family of peptides and peptide derivatives that bind with high specificity to fibrin, a protein found in blood clots.

The patent is entitled "Peptide-based Multimeric Targeted Contrast Agents." As issued, its term extends through July 30, 2022. The patent covers EP-2104R, EPIX's investigational fibrin-binding imaging agent, which is completing phase IIa clinical studies.

The company also announced that it has...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2006-03-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry